Ulcerative colitis

DR. DOUGLAS WOLF APPOINTED TO CROHN'S AND COLITIS FOUNDATION'S NATIONAL BOARD OF TRUSTEES

Retrieved on: 
Donnerstag, Mai 9, 2024
Health care, Crohn's disease, Capsule endoscopy, Research, Ulcerative colitis, IBD, Inflammatory bowel disease, Colonoscopy, Disease, Commitment, Medical director, Pharmaceutical industry

ATLANTA, May 9, 2024 /PRNewswire/ -- Dr. Douglas Wolf, United Digestive physician and Medical Director for the Center for Crohn's Disease & Ulcerative Colitis, has been appointed to the National Board of Trustees of the Crohn's and Colitis Foundation, the leading nonprofit organization focused on research and patient support for inflammatory bowel disease (IBD).

Key Points: 
  • Dr. Wolf's career spans four decades, during which he has dedicated himself to advancing the understanding and treatment of IBD through clinical practice, research, and patient advocacy.
  • He has conducted extensive clinical research on various aspects of IBD, including diagnostic testing, colonoscopy and capsule endoscopy, and biologic, small molecule, and nutritional therapy.
  • "I am deeply humbled and honored to accept this appointment to the Crohn's and Colitis Foundation's National Board of Trustees," expressed Dr. Wolf.
  • "Throughout my career, I have witnessed firsthand the profound impact that inflammatory bowel disease can have on individuals and their families.

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Donnerstag, Mai 9, 2024
American Academy, Ulcerative colitis, BDCA2, American Association of Immunologists, CDAI, American Academy of Dermatology, PD-1, IND, Week, AAI, Therapy, Patient, Graft-versus-host disease, Rheumatoid arthritis, AAD, Atopic dermatitis, BTLA, SAN, UC, Pharmaceutical industry

“This quarter, we continued to enroll patients globally across three Phase 2 trials for our two best-in-class checkpoint agonists: ANB032, our BTLA agonist, and rosnilimab, our PD-1 agonist.

Key Points: 
  • “This quarter, we continued to enroll patients globally across three Phase 2 trials for our two best-in-class checkpoint agonists: ANB032, our BTLA agonist, and rosnilimab, our PD-1 agonist.
  • Collaboration revenue was $7.2 million for the three months ended March 31, 2024, compared to $1.4 million for the three months ended March 31, 2023.
  • Research and development expenses were $37.0 million for the three months ended March 31, 2024, compared to $35.0 million for the three months ended March 31, 2023.
  • General and administrative expenses were $12.3 million for the three months ended March 31, 2024, compared to $10.8 million for the three months ended March 31, 2023.

Royalty Pharma Reports First Quarter 2024 Results

Retrieved on: 
Donnerstag, Mai 9, 2024
FDA, Ulcerative colitis, KarXT, Food, MorphoSys, European Commission, Marketing, New Drug Application, Cystic fibrosis, PDSS, PANSS, Tourette syndrome, Lupus, Docetaxel, Roche, Schizophrenia, Novartis, ADP, Pfizer, Incidence, Bristol Myers Squibb, Patient, Neurology, Acquisition, Sacituzumab govitecan, Olanzapine, Civil service commission, Multiple sclerosis, Positive, Vertex, Sanofi, Teva Pharmaceuticals, Astellas Pharma, European Medicines Agency, Lung cancer, Pharmaceutical industry

During 2024, Royalty Pharma announced new transactions of up to $619 million.

Key Points: 
  • During 2024, Royalty Pharma announced new transactions of up to $619 million.
  • In January 2024, Royalty Pharma acquired a royalty interest in ecopipam for an upfront payment of $49 million and up to $44 million in milestone payments contingent on the achievement of certain regulatory milestones.
  • In May 2024, Royalty Pharma announced a transaction to acquire royalties and milestones on frexalimab owned by ImmuNext for approximately $525 million in cash including estimated transaction costs.
  • Royalty Pharma has provided guidance for full year 2024, excluding transactions and borrowings announced after the date of this release, as follows:

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Donnerstag, Mai 9, 2024
Transfer, FDA, Research, Inflammation, Cell cycle, IND, CNS, Prostate cancer, AACR, Cancer, Autoimmunity, Lung cancer, Traffic barrier, MGD, Food, European Alliance, Conference, Roche, DDW, Pericarditis, Therapy, NSCLC, Rat, Ulcerative colitis, Poster, NLRP3, CCNE1, SCLC, Finance, Triple-negative breast cancer, Consultant, Public expenditure, Obesity, Gout, GLP, DSM-IV codes, Clinical trial, Toxicology, CDK2, G&A, Investigational New Drug, MYC, Research and development, EULAR, Carcinoma, Administration, Rheumatoid arthritis, Neoplasm, POC, Dermatology, Growth, Pharmaceutical industry

“We’re excited by the significant advances made across our entire portfolio, including both our oncology and immunology/inflammation programs,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.

Key Points: 
  • “We’re excited by the significant advances made across our entire portfolio, including both our oncology and immunology/inflammation programs,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.
  • The Company is on track to determine the recommended Phase 2 dose (RP2D) in Q2 2024 and report Phase 1 study results in H2 2024.
  • Announce the recommended Phase 2 dose for the MRT-2359 Phase 1/2 study in Q2 2024 and report Phase 1 clinical results in H2 2024.
  • Net Loss: Net loss for the first quarter of 2024 was $32.0 million, compared to $33.3 million for the fourth quarter of 2023.

Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Retrieved on: 
Donnerstag, Mai 9, 2024
Volunteering, FDA, Modulation, Ulcerative colitis, Solipsism syndrome, CDAI, Food, Risk, Molina Healthcare, NLRP3, Research and development, CAPS, Plasma, Webcast, Science, Administration, TYK2, IBD, Obesity, Week, SAD, European Medicines Agency, Patient, Treatment, Peripheral, EMA, Inflammation, CSF, Cardiovascular disease, Biomarker, MACE, G&A, SAN, UC, Pharmaceutical industry

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent pipeline and business progress.

Key Points: 
  • ET to discuss its first quarter 2024 financial results and provide a corporate update.
  • First Quarter 2024 Financial Results:
    Cash Position: Cash, cash equivalents and marketable securities were $302.6 million as of March 31, 2024.
  • Research and Development (R&D) expenses: R&D expenses were $33.7 million for the first quarter of 2024, compared to $35.4 million for the first quarter of 2023.
  • Net loss: Net loss was $38.6 million for the first quarter of 2024, compared to $38.9 million for the first quarter of 2023.

Arizona Digestive Health Expands Services with New Physicians in Scottsdale

Retrieved on: 
Donnerstag, Mai 9, 2024
FDA, Patient, Gastroenterology, Liver disease, Education minister, Cardiology, Communication, ADH, ICP, Ulcerative colitis, Retirement, IBD, Disease, Inflammatory bowel disease, Physician, Health, TigerConnect, UC, Medical device

Scottsdale, AZ, May 09, 2024 (GLOBE NEWSWIRE) -- Arizona Digestive Health is pleased to announce the addition of two respected physicians, Dr. Prabhakar Swaroop and Dr. Sirish Rao, to its Scottsdale location at 5111 N Scottsdale Road, Scottsdale, AZ .

Key Points: 
  • Scottsdale, AZ, May 09, 2024 (GLOBE NEWSWIRE) -- Arizona Digestive Health is pleased to announce the addition of two respected physicians, Dr. Prabhakar Swaroop and Dr. Sirish Rao, to its Scottsdale location at 5111 N Scottsdale Road, Scottsdale, AZ .
  • "We are excited to welcome Dr. Swaroop and Dr. Rao to our team at Arizona Digestive Health," says Dr. Parag Chokshi , president of Arizona Digestive Health.
  • “We want our patients to feel empowered.”
    Arizona Digestive Health in Scottsdale offers comprehensive gastroenterology services, including timely office and endoscopy appointments.
  • For more information or to schedule an appointment, visit Arizona Digestive Health - Scottsdale or call 602-254-6686 today.

Palisade Bio Appoints Margery Fischbein to its Board of Directors

Retrieved on: 
Dienstag, Mai 7, 2024
Ulcerative colitis, FBR, Economics, ImClone Systems, Harvard Business School, Therapy, Patient, Wall, Lehman Brothers, Street, Citigroup, Human Genome Sciences, Drug development, Biomarker, Chase Bank, Harvard University, Autoimmunity, UC, Pharmaceutical industry

Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Margery Fischbein to its Board of Directors.

Key Points: 
  • Ms. Fischbein is a highly experienced healthcare investment banker and accomplished biotechnology industry executive.
  • “We are excited to welcome Margery to our Board of Directors.
  • Prior to rejoining the banking industry, Ms. Fischbein held senior corporate positions at ImClone Systems and Human Genome Sciences.
  • Ms. Fischbein earned a master’s degree in business administration from Harvard Business School and a bachelor’s degree in economics from Harvard University.

Denver Digestive Health Specialists Expands Into Arvada

Retrieved on: 
Montag, Mai 6, 2024
CO, FDA, Patient, DDHS, Vedolizumab, Travel, Health, DRS, Ulcerative colitis, IBD, GI, Inflammatory bowel disease, Physician, UC, Nursing

Arvada, CO, May 06, 2024 (GLOBE NEWSWIRE) -- Denver Digestive Health Specialists, the premier gastroenterology practice in Denver, has opened  a new gastro clinic in Arvada, located at 9950 West 80th Avenue.

Key Points: 
  • Arvada, CO, May 06, 2024 (GLOBE NEWSWIRE) -- Denver Digestive Health Specialists, the premier gastroenterology practice in Denver, has opened  a new gastro clinic in Arvada, located at 9950 West 80th Avenue.
  • DDHS is a proud partner of GI Alliance , the leading physician-owned and -led network of gastroenterology practices in the U.S.
    Dr. Jonathan Scott heads up Denver Digestive Health’s Arvada location to expand services and offer geographic convenience to patients.
  • Denver Digestive Health Specialists aims to alleviate these challenges for patients so they can receive the quality medical care they deserve.
  • “Taking into account such factors as the patient’s concerns, lifestyle and medical history, I map out a strategy for my patients to achieve the most optimal medical outcome possible.”
    Denver Digestive Health Specialists in Arvada and Denver are now accepting appointments for new patients.

Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
Donnerstag, Mai 9, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Ulcerative colitis, Systemic scleroderma, Alopecia areata, HS, Research and development, Administration, Patient, TSLP, Record, Inflammation, Senior, Atopic dermatitis, Asthma, Autoimmunity, G&A, Chronic obstructive pulmonary disease, Pharmaceutical industry

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported its first quarter 2024 financial results, and recent business highlights.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported its first quarter 2024 financial results, and recent business highlights.
  • "Our recent financial and business highlights demonstrate how we continue to strengthen the company for future success.
  • The private placement by leading life sciences investors emphasizes the confidence in our pipeline of novel, dual-pathway antibodies for autoimmune and inflammatory diseases,” stated Robert Lisicki, CEO of Zura Bio.
  • Zura Bio anticipates that with the recent private placement factored in, its cash and cash equivalents are sufficient to fund planned operations through 2027.

Hawaii Specialty Pharmacy Announces New Ambulatory Infusion Centers to Serve Maui Community, Invites Local Media and Community Members to Opening Reception

Retrieved on: 
Mittwoch, Mai 8, 2024
Physician, Ulcerative colitis, Makawao, Hawaii, Patient, Cancer, Pharmacy, Hospital, Health, Heart, Chronic inflammatory demyelinating polyneuropathy, Nursing, Doctor of Pharmacy, Rheumatoid arthritis, HSP, Multiple sclerosis, CIDP

MAKAWAO, Hawaii, May 8, 2024 /PRNewswire/ -- Hawaii Specialty Pharmacy (HSP), a leading provider of specialty infusion pharmacy services with a focus on high-touch patient care and a mission to optimize patient health, today announced the opening of two new ambulatory infusion centers in Maui, Hawaii.

Key Points: 
  • MAKAWAO, Hawaii, May 8, 2024 /PRNewswire/ -- Hawaii Specialty Pharmacy (HSP), a leading provider of specialty infusion pharmacy services with a focus on high-touch patient care and a mission to optimize patient health, today announced the opening of two new ambulatory infusion centers in Maui, Hawaii.
  • "Empowering our community with comprehensive healthcare solutions has always been at the heart of Hawaii Specialty Pharmacy's mission," says George Kridner, PharmD, CEO of Hawaii Specialty Pharmacy.
  • Since its inception in 2018, Hawaii Specialty Pharmacy has distinguished itself by offering a local and personalized approach to patients managing complex and rare conditions.
  • Maui is excited to welcome these new infusion centers and their staff into the heart of our community."